Skip to main content

Table 2 Outcomes in HSV and non-HSV patients

From: HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients

   All patients (n = 153) Without HSV reactivation (n = 113) HSV reactivation (n = 40) p-value
Length of stay ICU Median (IQR) 11.5 [7; 21.5] 9 [6; 15] 23 [17; 40]  < 0.001
Death in ICU Number (%) 57 (37.3) 36 (31.9) 21 (52.5) 0.024
Death at day 60 Number (%) 61 (39.9) 38 (33.6) 23 (57.5) 0.014
HAP/VAP Number (%) 67 (43.8) 34 (30.1) 33 (82.5)  < 0.001
ICU-BSI Number (%) 38 (24.8) 20 (17.7) 18 (45) 0.001
IMV/ECMO Number (%) 89 (58.2) 54 (47.8) 35 (87.5)  < 0.001
  1. HSV-positive and -negative patients were compared with Chi-square, Fisher and Wilcoxon tests
  2. HSV Herpes simplex virus; IQR Interquartile range; ICU Intensive Care Unit; HAP Hospital-acquired pneumonia; VAP Ventilator-associated pneumonia; ICU-BSI Intensive care unit bloodstream infection. IMV Invasive mechanical ventilation. ECMO Extra-Corporeal Membrane Oxygenation